ACCESS Newswire·Oct 14, 2026, 9:00 AM ET

Positive Preliminary Results Presented at Annual American College of Gastroenterology Meeting for Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer

Jaguar Health's subsidiary Napo Pharmaceuticals presented positive preliminary results for an open-label pilot study of crofelemer powder for oral solution in adult Type 1 short bowel syndrome (T1SBS) patients at the ACG 2026 meeting.
The ongoing pilot study targets reduction of ostomy volume (OV) with a planned enrollment of 6 subjects & four participants have completed the protocol.
Results showed two subjects had a 5% average decrease in OV after 12 weeks of treatment, while three subjects experienced a 23% average increase in ostomy output after stopping the drug.
One subject reduced parenteral support (PS) volume by 9%, & three subjects improved urinary output by an average of 88% which was sustained for 4 weeks post-cessation.
No significant adverse events were observed & crofelemer was well tolerated in the study population.
Napo is conducting a multicenter, randomized, double-blind, placebo-controlled Phase 2 trial in adult T1SBS patients without colonic continuity, with results expected in the second half of 2027.
Previous data from pediatric studies presented at the 2026 ESPGHAN Meeting demonstrated substantial reductions in weekly PS needs for patients with microvillus inclusion disease (MVID) & SBS-IF.
The company remains focused on its global development program for rare disease intestinal failure, targeting a New Drug Application (NDA) filing for MVID in mid-2027.